BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

EWTX upcoming catalysts

Edgewise Therapeutics, Inc.: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 0 FDA event(s). Subscribe to EWTX (.ics).

Drugs: Sevasemten

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01 est.P2Edgewise Therapeutics, Inc. EWTXNCT05540860 A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)Duchenne Muscular Dystrophyactive not recruiting76

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-07P2Edgewise Therapeutics, Inc. EWTXNCT05291091 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)Becker Muscular Dystrophycompleted244

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.